Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
07
07
2021
accepted:
10
11
2021
revised:
21
09
2021
pubmed:
25
11
2021
medline:
14
5
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
Evaluate spontaneous closure of the patent ductus arteriosus (PDA) in extremely preterm infants and their respiratory outcomes, especially at <26 weeks gestational age (GA). Retrospective study in <29 weeks, admitted within 24 h after birth (Feb 2015 and Dec 2019). Infants without any intervention to promote ductal closure, ≥1 echocardiography, and alive at discharge were included. Two hundred and fourteen infants (average GA 26.3 ± 1.5 weeks) were included; 84 (39%) <26 weeks. PDA closed spontaneously in 194 (91%); 76/84 (90%) for infants <26 weeks. PDA closure was ascertained on an echocardiography performed at a median age of 36.4 [34.4-40.1] weeks. Rate of moderate-to-severe bronchopulmonary dysplasia decreased throughout the study period (OR for year of birth: 0.70 [95% CI: 0.57-0.87], p = 0.001). Majority of extremely preterm infants, including <26 weeks, had spontaneous closure of the ductus before term corrected age. There was a concomitant improvement of respiratory outcomes.
Identifiants
pubmed: 34815521
doi: 10.1038/s41372-021-01277-2
pii: 10.1038/s41372-021-01277-2
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
642-648Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Laughon M, O’Shea MT, Allred EN, Bose C, Kuban K, Van Marter LJ, et al. Chronic lung disease and developmental delay at 2 years of age in children born before 28 weeks’ gestation. Pediatrics. 2009;124:637–48.
pubmed: 19620203
doi: 10.1542/peds.2008-2874
Altit G, Dancea A, Renaud C, Perreault T, Lands LC, Sant’Anna G. Pathophysiology, screening and diagnosis of pulmonary hypertension in infants with bronchopulmonary dysplasia-a review of the literature. Paediatr Respir Rev. 2017;23:16–26.
pubmed: 27986502
Lemyre B, Moore G. Counselling and management for anticipated extremely preterm birth. Paediatr Child Health. 2017;22:334–41.
pubmed: 29485138
pmcid: 5804811
doi: 10.1093/pch/pxx058
Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. Jama. 2015;314:1039–51.
pubmed: 26348753
pmcid: 4787615
doi: 10.1001/jama.2015.10244
Semberova J, Sirc J, Miletin J, Kucera J, Berka I, Sebkova S, et al. Spontaneous closure of patent ductus arteriosus in infants ≤1500 g. Pediatrics. 2017;140:2.
doi: 10.1542/peds.2016-4258
Sung SI, Chang YS, Kim J, Choi JH, Ahn SY, Park WS. Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23-28 weeks of gestation. PLoS ONE. 2019;14:1–11.
doi: 10.1371/journal.pone.0212256
Rolland A, Shankar-Aguilera S, Diomandé D, Zupan-Simunek V, Boileau P. Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed. 2015;100:F55–8.
pubmed: 25169243
doi: 10.1136/archdischild-2014-306339
Urquhart DS, Nicholl RM. How good is clinical examination at detecting a significant patent ductus arteriosus in the preterm neonate? Arch Dis Child. 2003;88:85–6.
pubmed: 12495976
pmcid: 1719262
doi: 10.1136/adc.88.1.85
Benitz WE, Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics. 2016;137:1–6.
doi: 10.1542/peds.2015-3730
Benitz WE, Bhombal S. The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants. Semin Fetal Neonatal Med. 2017;22:302–7.
pubmed: 28724506
doi: 10.1016/j.siny.2017.07.004
Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Jama. 2018;319:1221–38.
pubmed: 29584842
pmcid: 5885871
doi: 10.1001/jama.2018.1896
Benitz W. Learning to live with patency of the ductus arteriosus in preterm infants. J Perinatol. 2011;31:S42.
pubmed: 21448203
doi: 10.1038/jp.2010.175
Benitz WE. Patent ductus arteriosus: to treat or not to treat? Arch Dis Child Fetal Neonatal Ed. 2012;97:F80–2.
pubmed: 22174019
doi: 10.1136/archdischild-2011-300381
Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30:241–52.
pubmed: 20182439
doi: 10.1038/jp.2010.3
Laughon M, Bose C, Benitz WE. Patent ductus arteriosus management: what are the next steps? J Pediatr. 2010;157:355–7.
pubmed: 20580017
doi: 10.1016/j.jpeds.2010.05.022
Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr. 2004;16:146–51.
pubmed: 15021192
doi: 10.1097/00008480-200404000-00005
Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr. 2007;150:216–9.
pubmed: 17307530
pmcid: 2723062
doi: 10.1016/j.jpeds.2006.12.048
Perez KM, Laughon MM. What is new for patent ductus arteriosus management in premature infants in 2015? Curr Opin Pediatr. 2015;27:158–64.
pubmed: 25689456
doi: 10.1097/MOP.0000000000000200
Chock VY, Punn R, Oza A, Benitz WE, Van Meurs KP, Whittemore AS, et al. Predictors of bronchopulmonary dysplasia or death in premature infants with a patent ductus arteriosus. Pediatr Res. 2014;75:570–5.
pubmed: 24378897
doi: 10.1038/pr.2013.253
Altit G, Saeed S, Beltempo M, Claveau M, Lapointe A, Basso O. Outcomes of extremely premature infants comparing patent ductus arteriosus management approaches. J Pediatr. 2021;235:49–57.
pubmed: 33864797
doi: 10.1016/j.jpeds.2021.04.014
Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatrics. 2018;197:300–8.
doi: 10.1016/j.jpeds.2018.01.043
Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013;13:59.
pubmed: 23601190
pmcid: 3637477
doi: 10.1186/1471-2431-13-59
Canadian Neonatal Network - Annual Report. Postnatal use of steroids for treatment of Chronic Lung Disease in GA < 29 weeks. Annual Report by the Canadian Neonatal Network (CNN). WebLink: http://www.canadianneonatalnetwork.org/portal/Portals/0/Annual%20Reports/2019%20CNN%20report%20final_links.pdf . 2019:1–145. Accessed November 2021.
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–9.
pubmed: 11401896
doi: 10.1164/ajrccm.163.7.2011060
Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am. 1996;43:409–32.
pubmed: 8614608
pmcid: 7127724
doi: 10.1016/S0031-3955(05)70413-2
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1.
pubmed: 413500
pmcid: 1396409
doi: 10.1097/00000658-197801000-00001
Papile L-A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529–34.
pubmed: 305471
doi: 10.1016/S0022-3476(78)80282-0
Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arc Dis Child Fetal Neonatal Ed. 2014;99:F99–F104.
doi: 10.1136/archdischild-2013-304695
Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risk scores. J Pediatr. 2001;138:92–100.
pubmed: 11148519
doi: 10.1067/mpd.2001.109608
CNN. Patient log—Admission screen definitions—Canadian Neonatal Network—Abstractor’s Manual. 2012. http://www.canadianneonatalnetwork.org/Portal/LinkClick.aspx?fileticket=I3jnvN9fGfE%3D&tabid=69 .
El-Khuffash AF, Jain A, McNamara PJ. Ligation of the patent ductus arteriosus in preterm infants: Understanding the physiology. J Pediatr. 2013;162:1100–6.
pubmed: 23410600
doi: 10.1016/j.jpeds.2012.12.094
Germain A, Nouraeyan N, Claveau M, Leone M, Sant’Anna G. “Optimal surfactant delivery protocol using the bovine lipid extract surfactant: a quality improvement study”. J Perinatol. 2021;41:17–23.
pubmed: 33011749
doi: 10.1038/s41372-020-00846-1
Weber SC, Weiss K, Bührer C, Hansmann G, Koehne P, Sallmon H. Natural history of patent ductus arteriosus in very low birth weight infants after discharge. J Pediatr. 2015;167:1149–51.
pubmed: 26239928
doi: 10.1016/j.jpeds.2015.06.032
Patel RM, Kandefer S, Walsh MC, Bell EF, Carlo WA, Laptook AR, et al. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med. 2015;372:331–40.
pubmed: 25607427
pmcid: 4349362
doi: 10.1056/NEJMoa1403489
Vollsæter M, Clemm HH, Satrell E, Eide GE, Røksund OD, Markestad T, et al. Adult respiratory outcomes of extreme preterm birth. A regional cohort study. Ann Am Thorac Soc. 2015;12:313–22.
pubmed: 25616079
doi: 10.1513/AnnalsATS.201406-285OC
Lazdam M, de la Horra A, Pitcher A, Mannie Z, Diesch J, Trevitt C, et al. Elevated blood pressure in offspring born premature to hypertensive pregnancy: is endothelial dysfunction the underlying vascular mechanism? Hypertension. 2010;56:159–65.
pubmed: 20479334
doi: 10.1161/HYPERTENSIONAHA.110.150235
Doyle LW, Cheong JLY. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia—who might benefit? Semin Fetal Neonatal Med. 2017;22:290–5.
pubmed: 28734731
doi: 10.1016/j.siny.2017.07.003
Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics. 2007;119:716–21.
pubmed: 17403842
doi: 10.1542/peds.2006-2806
Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117:75–83.
pubmed: 16396863
doi: 10.1542/peds.2004-2843
Doyle LW, Ehrenkranz RA, Halliday HL. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2014:CD001145.
Halliday HL. Update on postnatal steroids. Neonatology. 2017;111:415–22.
pubmed: 28538237
doi: 10.1159/000458460
Morales P, Rastogi A, Bez ML, Akintorin SM, Pyati S, Andes SM, et al. Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatr Cardiol. 1998;19:225–9.
pubmed: 9568218
doi: 10.1007/s002469900290
Takami T, Momma K, Imamura S. Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats. Circ J. 2005;69:354–8.
pubmed: 15731544
doi: 10.1253/circj.69.354
Keszler M, Sant’Anna G. Mechanical ventilation and bronchopulmonary dysplasia. Clin Perinatol. 2015;42:781–96.
pubmed: 26593078
doi: 10.1016/j.clp.2015.08.006
Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41–8.e6.
pubmed: 30340932
doi: 10.1016/j.jpeds.2018.09.012